Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to be Presented at the Annual Meeting of the European Society for Blood and Marrow Transplantation


Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that updated results from a Phase 1 clinical study of GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma and multiple myeloma, will be presented during an oral session at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which is being held March 22 through March 25, 2020, in Madrid, Spain.

Details about the presentation are as follows:

Time: Wednesday, March 25, 2020, at 11:00 a.m. CET
Abstract Number: OS22-1
Title: Results of a Phase 1 Trial of GDA-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)
Lead Author: Veronika Bachanova, M.D., Ph.D., Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
Location: Room N118

About GDA-201
Gamida Cell applied the capabilities of its NAM-based cell expansion technology to develop GDA-201, an innate natural killer (NK) cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs of NK cells expanded in culture. GDA-201 is in Phase 1 development through an investigator-sponsored study in patients with refractory non-Hodgkin lymphoma and multiple myeloma.1

GDA-201 is an investigational therapy, and its safety and efficacy has not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit https://www.gamida-cell.com.

1ClinicalTrials.gov identifier NCT03019666.


These press releases may also interest you

at 19:50
Faraday Future Receives Letter from Nasdaq Regarding Form 10-K Filing
Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") , a California-based global shared intelligent electric mobility ecosystem company, today announced that it received a letter (the "Nasdaq Letter") from The Nasdaq Stock...

at 19:50
Genifi Announces Full Year and Q4 2023 Results
Genifi Inc. (formerly Prodigy Ventures Inc.) ("genifi" or the "Company") today announced its financial results for the three months and year ended December 31, 2023. As previously reported, the Company sold TCB Corporation ("Prodigy Labs") on...

at 19:47
Sabre announces upcoming webcasts of its 2024 Annual Meeting of Stockholders and first quarter 2024 earnings conference call
Sabre Corporation ("Sabre") announced plans to host a live webcast of its 2024 Annual Meeting of Stockholders on April 24, 2024 at 10:30 a.m. ET.  The webcast will be accessible by visiting the Investor Relations section of Sabre's website...

at 19:38
Illinois Speaker Chris Welch Recommended by Proviso Township Democratic Organization to Serve as Committeeman
Illinois House Speaker Emanuel "Chris" Welch was unanimously recommended to serve as the new Proviso Township Committeeman in a meeting held Friday evening of the Executive Committee, replacing the late Karen Yarbrough....

at 19:08
Nium and Kapronasia Partner to Shed Light on Cross-border B2B Payment Challenges in Asia
Nium, the global leader in real-time, cross-border payments, and Asia's leading payments, banking, and capital markets research firm, Kapronasia, today launched "Breaking Borders: The Revolution of Real-Time Cross-Border B2B Payments in Asia" - a new...

at 18:13
Appsketiers Empowers Aspiring Entrepreneurs with Affordable, Custom App Development, Offering Unmatched Starting Prices
In a digital era where the app market continues to expand, driven by increased smartphone adoption and technological advancements, Appsketiers emerges as a beacon of hope for aspiring entrepreneurs and innovators. With a mission to democratize app...

More news about Science and technology...


News published on and distributed by: